Healthcare, Pharma & Life Sciences

Cambridge, Mass. – October 28, 2026 -- CREATE Medicines will present preclinical data showing complete B cell depletion in lymph nodes, spleen and bone marrow after low doses of its in vivo CAR-T therapy at the APLAR 2026 Congress in Seoul, running October 28 to November 1 at the COEX Convention & Exhibition Center.

Adam Raff presents mouse and primate data on October 31

Adam Raff, MD, PhD, SVP of Autoimmune Clinical Development, will deliver the oral abstract "In Vivo Generation of CAR-T Cells for the Treatment of B-cell Mediated Autoimmune Disease" in Abstract Session 2. The data come from mice and non-human primates. They show that low doses cleared B cells from the deep tissues where autoimmune disease takes hold.

INDIANAPOLIS – October 28, 2026 -- Carnyx Therapeutics has advanced its lead oral sleep candidate, CNYX-005, into Investigational New Drug (IND)-enabling development, bringing the preclinical asset closer to potential first-in-human studies.

Aged-rat data show 1.5 to 2 hours of added sleep

In recently reported preclinical findings, CNYX-005 increased total sleep time by roughly 1.5 to 2 hours versus controls in aged rats. The gain was driven primarily by increased non-rapid eye movement (NREM) sleep. Chief Medical Officer Chris Brearley said existing treatments are limited by safety, tolerability and long-term use concerns, which he cited as the case for additional options.

Irvine – October 28, 2026 -- SBC Medical Group Holdings (Nasdaq: SBC) will present at three investor conferences between Oct. 1 and Oct. 15, 2026, two of them in person in New York. The Medical Services Organization (MSO) will hold presentations and one-on-one meetings with institutional investors.

SBC Medical manages clinic brands across eight healthcare fields

The company provides management support in advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, hair loss treatment (AGA) and ophthalmology. It is expanding in the United States and Asia through direct operations and medical tourism initiatives.

SBC Medical listed on Nasdaq in September 2024. In June 2025, it was selected for inclusion in the Russell 3000 Index.

Global – October 27, 2026 -- Solid Biosciences has dosed the first participant in FALCON, a Phase 1b trial of SGT-212, its investigational gene therapy for Friedreich's ataxia (FA), and expects to release an initial data update in the second half of 2026, subject to patient enrollment.

FALCON tests a dual-route gene therapy in adults aged 18-40

FALCON is an open-label, dose-finding study designed to evaluate the safety and tolerability of SGT-212 in people aged 18-40 living with FA. Solid describes the approach as novel and first-in-class. It is the first-in-human study of SGT-212.

Intradentate nucleus infusion precedes intravenous delivery

Each participant receives an intradentate nucleus (IDN) infusion targeting the cerebellar dentate nuclei, followed by an intravenous (IV) infusion. Solid says the dual routes are intended to address the neurologic, cardiac and systemic manifestations of FA.

Hamburg – October 27, 2026 -- Mobil Krankenkasse has published its 2025 business report and transparency report, with the Innovation Fund project moVe-it as the central care initiative.

moVe-it targets post-stroke spasticity care through digital case management

The business report, titled "Gesundheit braucht ...", puts patient care at the center. It names three priorities: giving policyholders orientation, developing care services further and strengthening prevention.

Mobil Krankenkasse leads the moVe-it consortium, which includes partners from science and healthcare delivery. The project aims to improve care for people with spasticity after a stroke through digital, interdisciplinary care management.

SHANGHAI – October 27, 2026 -- Henlius' serplulimab combined with chemotherapy delivered a median overall survival (OS) of 12.4 months versus 10.2 months for atezolizumab plus chemotherapy in the U.S. ASTRIDE study of first-line extensive-stage small cell lung cancer (ES-SCLC). The company presented the data at the European Society for Medical Oncology (ESMO) Congress 2026.

ASTRIDE shows a numerical OS edge but no formal superiority test

The hazard ratio was 0.82 (95% CI, 0.56-1.20), at a median follow-up of 14.1 months and a data cutoff of February 18, 2026. The trial was descriptive, with no formal hypothesis testing for superiority or noninferiority planned.

One-year OS rates were 52.4% for serplulimab and 41.4% for atezolizumab. Two-year OS rates were 32.2% and 17.6%, respectively. The serplulimab arm had more patients with liver metastasis (49.5% vs 40.0%).

STOCKHOLM – October 27, 2026 -- Sobi raised its 2026 revenue growth guidance to high-teens to low-20s per cent at constant exchange rates (CER), up from mid- to high-teens, after third-quarter revenue grew 16 per cent at CER to SEK 9,124 M (7,776). Reported growth was 17 per cent, and year-to-date growth stands at 23 per cent at CER. The company also announced that CEO Guido Oelkers will step down no later than the end of January 2027.

Haematology revenue rises 29% as Altuvoct sales more than double

Haematology revenue increased 29 per cent at CER to SEK 6,171 M (4,771). Altuvoct sales reached SEK 1,729 M, up from SEK 769 M a year earlier. Doptelet added SEK 1,829 M (1,408).

Revenue from Sobi's strategic portfolio grew 25 per cent at CER to SEK 6,298 M (5,001).

Athens – October 27, 2026 -- Month 6 interim data comparing single-dose Cecolin 9 with Gardasil 9 were presented at the 38th Annual Conference of the International Papillomavirus Society (IPVS 2026), while final results from the Phase III SHINE I study are not expected until 2028.

Navrongo researcher presents Month 6 analysis of PATH's SHINE I study

Dr. Nana A. Ansah of Ghana's Navrongo Health Research Centre presented the interim analysis of PATH's Single-dose HPV Immunobridging Study with New Vaccines (SHINE I; CVIA 104). The Phase III, double-blind, randomized, multinational study runs in Ghana and the Philippines. It compares the immunogenicity and safety of single-dose Cecolin 9, developed by Xiamen Innovax Biotech Co., Ltd. (IX), with Gardasil 9.

Participants include girls aged 9–14 and young women aged 15–20.

United States – October 27, 2026 -- IntelePeer is marketing its SmartAgent Agentic AI platform to university dental schools, arguing that manual scheduling, billing follow-up and recall processes cost revenue and shape how students understand clinic operations.

Student clinics face higher no-show rates and thinner billing capacity

IntelePeer says no-shows in student clinics run higher than in private practice because the patient base skews toward price-sensitive individuals with weaker ties to a provider. Revenue recovery is further complicated by delayed billing cycles and the complexity of student-driven charting. Recalls and post-visit follow-up often depend on whichever staff member has time.

United States – October 27, 2026 -- Healthcare faces a projected shortage of up to 3.2 million workers by 2026, and IntelePeer argues that gap is making per-seat enterprise software economically obsolete as buyers shift from purchasing tools to purchasing completed work.

Per-seat pricing fails when healthcare cannot fill the seats

Enterprise software has been priced per seat, per user, per license for two decades, on the assumption that the human is the engine and software makes that engine faster. The IntelePeer analysis says that assumption breaks where labor is the bottleneck. Administrative roles are among the hardest to fill and retain, according to the Mercer / Oliver Wyman projection it cites, and wage inflation is compressing margins.